Skip to main content

Currently Skimming:

1 Introduction
Pages 1-4

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 1...
... 1 The planning committee's role was limited to planning the workshop, and the workshop summary has been prepared by the workshop rapporteurs as a factual summary of what occurred at the workshop. Statements, recommendations, and opinions expressed are those of individual presenters and participants, and are not necessarily endorsed or verified by the Institute of Medicine, and they should not be construed as reflecting any group consensus.
From page 2...
... By contrast, he said the pharmaceutical industry has a much more welldeveloped understanding of these issues. Another hindrance for companies developing therapeutic neuromodulatory devices is that these organizations are typically small relative to those developing drug therapies, and therefore they may have fewer resources to devote to the pursuit of endorsement by regulators and payers, said Ana Maiques, chief executive officer of Neuroelectrics.
From page 3...
... • Explore current and potential use reimbursement practices for therapeutic use of non-invasive neuromodulation devices. o Explore the evidence base and acceptable therapeutic outcome measures utilized in reimbursement decisions.
From page 4...
... Chapters 4 and 5 discuss therapeutic and non-therapeutic uses of neuromodulation, including its use as a tool for diagnosis, presurgical mapping, and research. Chapter 6 explores the use of neuromodulation to enhance brain function and performance, followed by a discussion of the ethical issues related to the use of neuromodulatory technologies in Chapter 7.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.